LambdaVision, based in Woodbridge, CT, is engineering a protein-based artificial retina that leverages microgravity manufacturing to replicate the light-absorbing properties of human photoreceptor cells. The device is designed to activate surviving neuroreceptors in patients blinded by conditions such as retinitis pigmentosa and age-related macular degeneration. Led by CEO Nicole Wagner, the company has established manufacturing and quality-control protocols aboard the International Space Station, positioning its technology among the first clinical candidates produced in space. LambdaVision plans to use its recent seed financing to advance preclinical studies and expand space-enabled production capacity. The photoactive protein approach aims to provide a more natural, vision-restoring solution compared with current implants. While still pre-revenue and pre-clinical, the company’s work in microgravity lays the groundwork for future space-based biomedical research and commercialization.

Total raised

$8M

Funding rounds

3

Latest round

Seed

Latest activity

Nov 2025